Neurocrine Biosciences, Inc. announced new patient-reported post-hoc data from the KINECT-HD study, highlighting significant reductions in both cognitive and motor-related burdens among adults treated for Huntington's disease chorea with once-daily INGREZZA capsules. These analyses will be presented at the 2025 Advanced Therapeutics in Movement & Related Disorders Congress.
KINECT-HD is the first and only clinical study to demonstrate measurable changes in cognitive and motor disease burden with a vesicular monoamine transporter 2 inhibitor (INGREZZA) in patients treated for chorea. At maintenance, INGREZZA demonstrated numerically larger reductions compared with placebo across all 18 cognition items and 32 of the 33 motor items.
Statistically significant improvements with INGREZZA were observed across a range of items, including memory loss, reduced decision-making abilities, trouble finding the right word, limitations with mobility/walking, abnormal movements, impaired coordination, difficulty sitting still, problems knocking things over, and problems swallowing. These findings highlight INGREZZA's ability to reduce additional challenges faced by those living with Huntington's disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.